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Combinatorial Small-Molecule Therapy Prevents Uropathogenic
Escherichia coli Catheter-Associated Urinary Tract Infections in Mice
Pascale S. Guiton,a Corinne K. Cusumano,a Kimberly A. Kline,a,e Karen W. Dodson,a Zhenfu Han,b James W. Janetka,b
Jeffrey P. Henderson,c,d Michael G. Caparon,a,c and Scott J. Hultgrena,c
Department of Molecular Microbiology and Microbial Pathogenesis,a Department of Biochemistry and Molecular Biophysics,b Center for Women’s Infectious Disease
Research,c and Department of Internal Medicine (Infectious Diseases),d Washington University School of Medicine, St. Louis, Missouri, USA, and Department of Laboratory
and Genomic Medicine, Singapore Centre on Environmental Life Sciences Engineering School of Biological Sciences, Nanyang Technological University, Singaporee
Catheter-associated urinary tract infections (CAUTIs) constitute the majority of nosocomial urinary tract infections (UTIs) and
pose significant clinical challenges. These infections are polymicrobial in nature and are often associated with multidrug-resis-
tant pathogens, including uropathogenic Escherichia coli (UPEC). Urinary catheterization elicits major histological and immu-
nological alterations in the bladder that can favor microbial colonization and dissemination in the urinary tract. We report that
these biological perturbations impact UPEC pathogenesis and that bacterial reservoirs established during a previous UPEC in-
fection, in which bacteriuria had resolved, can serve as a nidus for subsequent urinary catheter colonization. Mannosides, small
molecule inhibitors of the type 1 pilus adhesin, FimH, provided significant protection against UPEC CAUTI by preventing bacte-
rial invasion and shifting the UPEC niche primarily to the extracellular milieu and on the foreign body. By doing so, mannosides
potentiated the action of trimethoprim-sulfamethoxazole in the prevention and treatment of CAUTI. In this study, we provide
novel insights into UPEC pathogenesis in the context of urinary catheterization, and demonstrate the efficacy of novel therapies
that target critical mechanisms for this infection. Thus, we establish a proof-of-principle for the development of mannosides to
prevent and eventually treat these infections in the face of rising antibiotic-resistant uropathogens.
Catheter-associated urinary tract infections (CAUTIs) often in-volve Gram-positive and/or Gram-negative bacterial coloni-
zation and biofilm aggregation on the surface of indwelling uro-
logic devices such as urinary catheters. These biofilms and the
increasing occurrence of multidrug-resistant pathogens render
treatment very difficult (22, 49, 57). Uropathogenic Escherichia
coli (UPEC), the primary cause of community-acquired urinary
tract infections (UTIs), account for 50% of nosocomial UTIs, in-
cluding CAUTIs (27). However, very little is known about its
pathogenesis after urinary catheterization, which results in the
disruption of the normal mechanical and antimicrobial defenses
of the bladder (9, 17, 43, 44). Previous reports using humanbiopsy
specimens and rodent models of infections have shown that the
catheterized bladder is edematous and highly inflamed with im-
mune cell infiltration and high levels of proinflammatory cyto-
kines, an environment very different from that which UPEC ini-
tially encounters upon infection of a noncatheterized bladder (17,
18, 28, 44). We hypothesized that these profound catheter-related
changes may affect UPEC pathogenesis.
The UPEC pathogenic cascade has been extensively character-
ized in a noncatheterized murine model of cystitis (21, 25, 30, 31,
35, 37, 38, 62). UPEC strains encode numerous adhesive pilus
fibers assembled by the chaperone/usher pathway (CUP) (50, 58)
that are often tipped with adhesins that bind to receptors with
stereochemical specificity (10, 23), thus facilitating colonization
and biofilm formation (31, 45, 62). Almost all UPEC strains en-
code the class of CUP pili known as type 1 pili (24) that are tipped
with the mannose-binding FimH adhesin (23). FimH is known to
bind highly homologous mannosylated uroplakins that coat the
luminal surface of both the human and murine bladder (55, 64,
65) and N-linked oligosaccharides on 1 and 3 integrins, which
are expressed throughout the urothelium (13). Further, FimHhas
been shown to facilitate the bacterial colonization and invasion of
human bladder tissue culture cells (5, 25, 41, 62), human ureter
tissues, and mouse bladder epithelial cells. Internalized UPEC are
exocytosed in a TLR4-dependent process (54); however, bacteria
within superficial epithelial cells can escape into the host cell cy-
toplasm, subverting expulsion and innate defenses. Within the
cytoplasm, UPEC strains replicate and aggregate into large bio-
film-like intracellular bacterial communities (IBCs) in a FimH-
dependent process (2, 25, 62). Subsequently, UPEC strains dis-
perse from mature IBCs, escape into the bladder lumen, and
reinitiate the process by binding and invading naive epithelial
cells. In addition to IBCs, UPEC strains are also able to establish
quiescent intracellular reservoirs (QIRs), consisting of small num-
bers of intracellular UPEC that can persist in a dormant state,
tolerant to antibiotic therapy, andwhich can subsequently serve as
seeds for recurrent infection (36, 37, 52). Filamentation and IBC
formation has been documented in samples from human clinical
studies (47). In agreement with these findings and in support of
a role for FimH in humans, it has been shown that the fimH
gene is under positive selection in human clinical UPEC iso-
lates (5, 46, 60).
Detailed understanding of the critical steps of this pathogenic
cascade has led to the development of small-molecule inhibitors
called mannosides (20) that bind to FimHwith affinities 200,000-
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fold greater than mannose (20), thus inhibiting UPEC binding
and invasion of the superficial umbrella cells (in UTIs) (20).Man-
nosides such as mannoside 6 (20) have been shown to be orally
bioavailable in a murine model (8, 19). Oral administration is
able to efficaciously treat chronic UTI via a potent fast-acting
mechanism (8) that is capable of potentiating the efficacy of
trimethoprim-sulfamethoxazole (TMP-SMZ) (8).
In this report, an optimized murine model of foreign body-
associatedUTI that closelymimics CAUTI (18) was used to inves-
tigate the consequences of urinary catheterization on the patho-
physiology ofUPEC infection. For these studies, the contributions
of several UPEC virulence mechanisms, including type 1 pili, IBC
formation, and UPEC reservoirs from prior UTI episodes, were
assessed. The results obtained indicate that urinary catheteriza-
tion provides UPEC with a more favorable environment for ex-
tracellular colonization of the urinary tract with the opportunity
to exploit the ability to form type 1 pilus-mediated biofilms on the
surface of the foreign body. Prophylactic administration of man-
nosides, which blocked biofilm formation on silicone in vitro, po-
tentiated the efficacy of TMP-SMZ in preventing murine CAUTI.
This report provides important insights into the mechanisms un-
derlying UPEC-mediated CAUTI and informs efforts to design
better therapeutic approaches to prevent and potentially treat
these infections.
MATERIALS AND METHODS
Bacterial strains and growth conditions. All strains used in the present
study and their characteristics are listed in the Table 1. Unless otherwise
specified, a single colony of E. coli grown on a Luria-Bertani (LB) agar
(Becton Dickinson) plate supplemented with appropriate antibiotics was
inoculated into LB broth and grown statically at 37°C for 18 h before use
in the indicated assays.
In vitro cultivation and quantification of biofilms. Biofilms on all-
silicone Foley catheters (Bard Medical, GA) or silicone tubing (Thermo
Fisher Scientific Inc., PA) were grown as described by Ferrieres et al. (14)
and modified as follows. All tubing and connectors in the system were
autoclaved and ethanol sterilized prior to use. The system was assembled
similar to the previously described flow chamber system (6). Priming of
the catheter or the silicone tubing occurred at 37°C for 20 min by flowing
prewarmed pooled human urine. Urine was collected from healthy vol-
unteers as approved by the Institutional Review Board of Washington
University in St. Louis. Pooled samples were spun at 10,000  g for 15
min, supernatants were then filter-sterilized through 33-m-pore-size
filters, and, if necessary, stored at 4°C for nomore than 3 days. Portions (3
ml) of stationary-phase E. coli from overnight cultures diluted to 1 106
to 2  106 CFU/ml in human urine were injected into the catheter or
silicone tubing using a 30-ml gauge needle. The bacteria were allowed to
attach to the substratum for 1 h before urine flow via Watson-Marlow
peristaltic pump 205S was resumed at 0.5 ml min1. When indicated,
urine was supplemented with 1%methyl mannose (Sigma, St Louis, MO)
prior to the experiment. After 24 h, the remainingmediumwas exchanged
for sterile double-distilled H2O (ddH2O) that was allowed to flow at 0.5
ml min1 to remove the residual urine and nonadherent bacteria in the
system. The liquid from the catheter or silicone tubing was then removed
by capillary action onto absorbent paper. The tubing was aseptically cut
into pieces for CFU enumeration or crystal violet staining, respectively.
For CFU enumeration, at least three pieces (1 cm in length) of incubated
tubing were separately further cut into smaller pieces and placed into 1ml
of phosphate-buffered saline (PBS). Adherent cells were detached by son-
ication (10 min) and vigorous vortexing (3 min). Viable bacterial counts
were assessed by serial dilution on LB plates with appropriate antibiotics.
Crystal violet staining was used to determine biofilm biomass. At least
three pieces of incubated tubing (3 cm in length) were filled with 0.5%
crystal violet at room temperature for 10min. Excess dye was removed by
three washes with ddH2O and dried by capillary action on absorbent
paper. The bound crystal violet was then dissolved in 200l of 33% acetic
acid, and the absorbance was measured at 595 nm. Biofilm was quanti-
tated as CFU/ml per cm2 or as theA595/cm
2. The experiment was repeated
at least three times with different urine samples.
Animal implantation and infections. Six- to seven-week-old female
wild-type C57BL/6Ncr mice purchased from the National Cancer Insti-
tute (NCI) were used in the present study. Experiments were performed
after 1-week adaptation in the animal facility after arrival from the NCI.
Animals were implanted and infectedwith the indicated bacterial strain as
previously described (18). Briefly, 7- to 8-week-old female mice were
anesthetized by inhalation of isoflurane and transurethrally implanted
with platinum-cured silicone tubing (4 to 5 mm in length). Immediately
after implantation, 50l of ca. 1 107 to 2 107 CFU bacteria in 1 PBS
were introduced into the bladder lumen by transurethral inoculation.
Nonimplanted animals were inoculated in the same manner. Animals
were sacrificed at the indicated time points by cervical dislocation under
anesthesia inhalation. Bladders and kidneys were aseptically harvested.
Subsequently, the silicone implant was retrieved from the bladder when
present, placed in PBS, sonicated for 10 min, and then vortexed at maxi-
mum speed for 3 min. The bladder and kidneys from each mouse were
homogenized in PBS. Samples were serially diluted and plated on LB agar
plates supplemented with appropriate antibiotics. CFU were enumerated
after 24 h of incubation at 37°C. In all cases, experiments were performed
at least twice with n 5mice/strain/condition. All studies and procedures
were approved by the Animal Studies Committee at Washington Univer-
sity School of Medicine.
Mannoside and antibiotic treatment. For pretreatment experi-
ments, 50 l of mannoside (mannoside 6; 5 mg/kg [mouse body
weight]) or PBS was administered intraperitoneally (i.p.) 30 min prior
TABLE 1 Strains used in this study
Strain
Relevant antibiotic
resistancea Characteristics Source or reference
UTI89 Parental UPEC UTI89 strain, cystitis isolate 3
UTI89fimH UTI89 with an in-frame deletion of fimH, type 1 pilus defective 4
UTI89sfaA-H UTI89 with an in-frame deletion of sfa operon, S pilus defective This study
UTI89sfaA-HfimB-H Kanr Cmr UTI89 with in-frame deletions of the sfa operon and the fim operon
from fimB to fimH, S and type 1 pilus defective
This study
UTI89csgA UTI89 with an in-frame deletion of csgA, curli deficient 1
UTI89csgBcsgG UTI89 with in-frame deletions of csgB and csgG, curli deficient 1
UTI89HK::GFP Kanr UTI89 with an insertion of a kanamycin cassette and GFP at the HK
site
5
UTI89pCOMGFP Kanr UTI89 ectopically expressing GFP from pCOM plasmid 2, 5
a Cmr, chloramphenicol resistance; Kanr, kanamycin resistance.
Mannosides as Prophylactic Agents against UPEC CAUTI
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to implantation as previously described (8). As indicated for preinfec-
tion treatment, trimethoprim-sulfamethoxazole (TMP-SMZ) was added
to the drinking water for 3 days prior to infection at 54 and 270 g/ml,
respectively. The drinking water was changed every 24 h. To assess the
effects of mannoside 6 and/or TMP-SMZ on established infections, ani-
mals were implanted and infected for 24 h. At 24 h postinfection (hpi),
TMP-SMZ was added to the drinking water at the concentrations indi-
cated above, and mannoside 6 or PBS was administered i.p. 6 h prior to
sacrifice. Animals were sacrificed 48 hpi.
UPEC reservoir-derived colonization. Nonimplanted animals were
infectedwithUTI89HK::GFP as described above. At 14 days postinfection
(dpi), urine was collected, serially diluted, and plated for CFU. Animals
with bacterial loads greater than the limits of detection in each experiment
(200 or 400 CFU/ml) were determined to be bacteriuric and eliminated
from further analyses (see Fig. S3A in the supplementalmaterial). A subset
of the remaining nonbacteriuric animals was implanted for 3 or 5 days,
while the others remained nonimplanted and served as a control group for
reinfection events. Bacterial reservoir-mediated colonization after im-
plantation was assessed by CFU enumeration of bacteria on implants and
in the bladders 3 or 5 days postimplantation (17 or 19 dpi). Only abacte-
riuric animals with UTI89HK::GFP titers104 CFU on implants or blad-
ders at 17 or 19 dpi were considered reemergence events.
IBC enumeration and visualization. Implanted and nonimplanted
animals were infected with UTI89 for 6 h. When indicated, mannoside 6
(5mg/kg) or PBSwas administered i.p. at 30min prior to implantation. At
6 hpi, the bladderswere harvested, bisected, splayed on silicone plates, and
fixed in 2% paraformaldehyde. LacZ staining of whole bladders was per-
formed as previously described (26). Punctate violet spots characteristic
of IBCs were enumerated by light microscopy.
For IBCvisualization, animalswere infectedwithUTI89 constitutively
expressing green fluorescent protein (GFP), i.e., UTI89pCOM-GFP. At
the indicated time point, bladders were removed, bisected, splayed, and
fixed as described above. The splayed bladders were then incubated for 20
min at room temperature with Alexa Fluor 633-conjugated wheat germ
agglutinin (WGA [Molecular Probes]; 1:1,000 in PBS) for staining of the
bladder surface and, when indicated, SYTO83 (1:1,000 in PBS) to stain the
bacteria. Bladders were rinsed with PBS, mounted using Prolong Gold
antifade reagent (Invitrogen), and examined with a Zeiss LSM510 confo-
cal laser scanning microscope under a 63 objective lens. SYTO83 and
WGA were excited at 543 and 633 nm, respectively.
Gentamicin protection assay. To quantify intracellular and extracel-
lular bacteria, bladders were aseptically harvested at 3 and 6 hpi. Bladders
were cut in four parts and washed three times in 500 l of PBS. The wash
fractions were pooled and centrifuged at 500 rpm for 5 min to pellet
exfoliatedbladdercells.Thesupernatantswere thenseriallydilutedandplated
onLBagar supplementedwith appropriate antibiotics,whichwere incubated
at 37°C for 24 h to obtain extracellular bacterial CFU counts. Rinsed bladders
were then treated with 100 g of gentamicin/ml for 90 min at 37°C. After
gentamicin treatment, the bladder tissue was washed twice with PBS to elim-
inate residual antibiotics andhomogenized in 1ml of PBS, andbacterial CFU
counts of were determined as described above to determine the levels of in-
tracellular bacteria (protected from gentamicin killing).
Statisticalmethods.Comparisons between groupswere conducted by
nonparametric Mann-Whitney U test using GraphPad Prism (GraphPad
software, version 5). Values below the limit of detection for in vivo exper-
iments (20 CFU for organs and 10 CFU for implants) were assigned the
appropriate limit of detection for statistical analyses. All tests were two
tailed, and a P value	 0.05 was considered significant. Colonization and
infectionwere defined as organs or implants with bacterial titers above the
limit of detection.
RESULTS
UPEC adherence, invasion, and IBCmorphology are unaltered
in catheterized bladders. IBC formation occurs in the pathogen-
esis of UPEC in noncatheterized patients (47) and has been shown
in mouse models to be critical for infection (25, 62). To assess the
effects of urinary catheterization on IBC formation, 4- to 5-mm
platinum-cured silicone tubing sections were implanted in the
bladders of C57BL/6Ncr female mice, which were then immedi-
ately infected with 1 107 to 2 107 CFU of the well-character-
ized virulent UPEC strain UTI89 by transurethral catheterization.
Gentamicin protection assays performed at 3 hpi revealed no sig-
nificant difference (P  0.05) in either the extracellular or intra-
cellular UPEC populations in the presence or absence of implants
(see Fig. S1 in the supplemental material), indicating no gross
defect in bacterial invasion in implanted animals in the first 3 h of
infection. However, by 6 hpi, IBC formation was significantly re-
duced in implanted bladders compared to nonimplanted animals,
as assessed by LacZ staining and confocal scanning laser micros-
copy (CSLM) (Fig. 1A). Implanted animals had a median of 8
IBCs/bladder (P  0.0044; Fig. 1B) compared to nonimplanted
animals, in which IBC numbers ranged up to250 IBCs/bladder
with a median of 55 IBCs/bladder. IBC morphology did not ac-
count for this difference in implanted animals since the IBCs
formed in implanted animals were observed to have the same
dimensions as those produced in nonimplanted bladders (Fig.
1C), as seen by CLSM analysis. However, the bladders of im-
planted animals appeared to have more extensive exfoliation than
nonimplanted animals at 6 hpiwithUPECcolonization selectively
localized in the remaining umbrella cells and not in the exposed
underlying epithelium, as determined by CLSM analysis (see Fig.
S2 in the supplemental material). The bacterial CFU were similar
in the bladders of implanted and nonimplanted animals (data not
shown, but see Fig. 3). The discrepancy between IBC number and
CFU in implanted bladders suggested that in the implanted mice,
an increased proportion of the CFU were comprised of niches
FIG 1 Uropathogenic E. coli produces IBCs in the superficial umbrella cells of
implanted bladders. (A) Representative images of splayed bladders of female
C57BL/6Ncrmice infected with UTI89 at 6 hpi in the absence (nonimplanted)
or presence (implanted) of implants after LacZ staining. Each black arrow
indicates a purple speck, indicative of an IBC. (B) Quantification of IBC for-
mation following LacZ staining at 6 hpi. Each symbol represents IBC number
from a single mouse from two independent experiments with n  5/group.
The P value was obtained using the Mann-Whitney U test. (C) Representative
CLSM images of whole bladders from nonimplanted and implanted animals
infectedwithUTI89 ectopically expressingGFP (green), stainedwithDNAdye
SYTO83 (red), and an Alexa Fluor 633 conjugate of WGA (blue) reveal the
presence of IBC within umbrella cells. Scale bar, 20 m.
Guiton et al.
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outside of IBCs such as in extracellular niches or non-IBC intra-
cellular niches. Together, these findings indicate that urinary cath-
eterization alters the pathogenic cascade of UPEC resulting in de-
creased IBC formation. This is likely due to increased exfoliation
in catheterized bladders.
Bacteria originating from existing UPEC reservoirs can seed
urinary implant colonization. One troubling possible outcome
of the UPEC pathogenic cascade is the establishment of quiescent
intracellular reservoirs (QIRs) in the underlying epithelial layers.
QIRs have been defined as intracellular bacterial reservoirs of 101
and 104 CFU/bladder established during the course of an active
UTI that persist in the bladder tissue even after clearance of bac-
teriuria (36, 37, 52). Bacteria from these QIRs can reemerge upon
stimulation of uroepithelial turnover (37) and have been shown to
seed recurrent UTIs (rUTIs) (52). We have previously shown that
urinary catheterization causes damage to the protective uroepi-
thelial layer (9, 17, 18, 28, 44). Thus, we hypothesized that urinary
catheterizationmight perturb existing UPEC reservoirs and result
in bacteriuria, catheter colonization, and further dissemination.
To test this hypothesis, mice were infected with 1 107 to 2 107
CFU UTI89HK::GFP, and infection was allowed to resolve over
the course of 2weeks. On day 14 postinfection, urinewas collected
from each animal to assess their bacteriuric state (see Fig. S3A in
the supplementalmaterial) prior to urinary implantation of a sub-
set of the animals. Animals with urine titers above the limit of
detection (200 or 400 CFU/ml) in each experiment were consid-
ered bacteriuric with active (unresolved and or recurrent) infec-
tion and were removed from further analyses. Only abacteriuric
animals (i.e., with urine titers at the limit of detection) presumed
to either have completely cleared the infection or to have bacterial
reservoirs within the bladder were used for further analyses. At 3
or 5 days postimplantation, bacterial titers from implants and
bladder were assessed to determine whether a previously estab-
lished reservoir could serve as a nidus for CAUTI. On day 3 post-
implantation, UPECUTI89HK::GFP biofilms had formed on im-
plants in 2 of 25 implanted mice (
8%). One implanted mouse
had bladder colonization greater than 104 CFU/ml compared to
none of the 21 similarly infected but nonimplanted abacteriuric
animals (Fig. 2A). There was no significant difference in bladder
colonization between groups at 3 dpi. For mice assessed at 5 days
postimplantation, UTI89HK::GFP biofilms were recovered from
implants of 4 of 31 implanted animals (
13%) with 2 of the mice
having bladder titers104 CFU/ml (Fig. 2B) compared to 0 of 21
in nonimplanted animals. Interestingly, there were overall signif-
icantly fewer bacteria recovered from the bladders of implanted
animals compared to nonimplanted animals at 5 dpi (P 0.0015),
possibly the result of implant induced exfoliation of the uroepi-
thelium, which is thought to be part of an innate defense to clear
tissue associated bacteria (35). Treatment of UPEC-infected mice
at 14 dpi with protamine sulfate, a chemical that leads to exfolia-
tion of the superficial umbrella cells of the uroepithelium, resulted
in clearance of tissue-associated bacteria in 100% of treated ani-
mals (37). Figure S3B in the supplemental material matches the
urine titers on day 14, whichwere at the level of detection, with the
implant and bladder titers on day 17 or 19 postinfection for each
of the reinfected animals. Together, these findings indicate that
bacteria from previously established reservoirs can reemerge and
colonize the urinary catheter.
FimH is required for biofilm formation andUPEC coloniza-
tionof the urinary tract after catheter implantation.Biofilm for-
mation is a critical component of CAUTI pathophysiology (49,
57). We have previously shown that UPEC is able to produce
biofilms on the surface of the foreign body and is recovered from
the catheterized murine bladder at high titers with a median of
1.9 105 at 24 hpi (18). As discussed above, type 1 pili are UPEC
virulence factors (42) that have been shown to be critical in blad-
der colonization, IBC formation, and other aspects of UPEC uro-
pathogenesis. In addition, type 1 pili have been shown to be im-
portant in biofilm formation in vitro (48). Other UPEC fibers
associated with biofilm formation include S pili, curli, and flagella
(4, 11, 32, 39, 63). Thus, we assessed the contribution of each of
these fibers to biofilm formation in vitro on silicone tubing in
filtered human urine under flow conditions and UPEC-mediated
CAUTI in vivo. Deletion of the fimH gene significantly reduced
biofilm formation on silicone tubing in human urine in vitro (P	
0.0001) as measured by lower biomass (Fig. 3A) and an 
2-fold
reduction in adherent viable bacteria (Fig. 3B). In contrast, dele-
tions of the sfa operon (S pili), csgA (curli) or fliC (flagella) had no
effect on biofilm formation under these conditions (data not
shown).
In vivo, UTI89fimH was severely attenuated in the murine
model of foreign body-associated UTI (Fig. 3C) similar to what
has been seen previously in themurinemodel of cystitis (5, 31, 35,
62). UTI89fimH displayed3 log fewer CFU in the bladder at 24
hpi and did not ascend to the kidneys (see Fig. S4A in the supple-
mental material). Further, deletion of fimH significantly reduced
the ability of UTI89 to colonize the implants (P	 0.0001). Similar
to the in vitro experiments, S pili and curli were not required for
CAUTI. The strains UTI89sfaA-H and UTI89csgA behaved
identically to wild-type UTI89 (see Fig. S4A and B in the supple-
FIG 2 UPEC reservoir reactivation can lead to urinary implant and bladder
colonization. Graphs represent bacterial titers in log scale recovered from im-
plants and homogenized bladders of nonimplanted or implanted for 3 days
(A) or 5 days (B) animals that were nonbacteriuric and previously infected for
14 dpi with UTI89HK::GFP. Horizontal dashed lines represent the limit of
detection for viable bacteria. Each symbol represents a mouse from two inde-
pendent experiments with n  10 to 20/group/experiment. The horizontal
bars represent the median of each data set. The P value was determined by
using the Mann-Whitney U test.
Mannosides as Prophylactic Agents against UPEC CAUTI
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mental material). A double deletion of both sfaA-H and fimB-H
recapitulated the UTI89fimH phenotype (see Fig. S4A in the
supplemental material). Although colonization of the implants
was significantly reduced in the fimH strain, residual binding to
implants and bladders was detected, which was therefore presum-
ably mediated by other pili or biofilm determinants. Together,
these data strongly argue that the type 1 pilus tip adhesin FimH is
a critical determinant of UPEC virulence in mediating biofilm
formation and virulence during CAUTI.
Mannoside treatment reduces IBC formation.Having estab-
lished that FimH is required for UPEC virulence in implanted
bladders, we investigated type 1 pili as a potential therapeutic tar-
get for CAUTI using small molecule inhibitors called mannosides
designed to block the function of the type 1 pilus tip adhesin
FimH.We first assessed the ability of methyl--D-mannopyrano-
side (methyl mannose) to block UTI89 biofilm formation on sil-
icone tubing in human urine under flow conditions. 1% methyl
mannose significantly blocked the ability of UTI89 to form bio-
films, as measured by reduced biomass (P 0.0022) and reduced
biofilm-adherent cells (P 0.0012), compared to untreated con-
trols (see Fig. S5 in the supplemental material), an effect similar to
whatwas observed for the deletion of fimH (Fig. 3A).Methylman-
nose is a FimH antagonist, thus confirming the critical role of type
1 pili in biofilm formation on silicone tubing in urine as was pre-
viously described for biofilms formed in LB medium (45).
Methyl mannose exhibits poor bioavailability (1), whereas
mannoside compounds 6, 8, and 10 have recently been shown to
be orally bioavailable (8, 19) and potent therapeutics in the treat-
ment and prevention of acute and chronic UPEC infections (8).
Mannoside 6 is
1,000-fold more active in inhibiting FimH than
are methyl mannose and heptyl mannose (which is a more potent
inhibitor of FimH thanmethyl mannose) both in vitro and in vivo
(8, 15, 20, 61). Thus, mannoside 6 was tested for its therapeutic
potential to prevent CAUTI.Mice were treated i.p. with saline or 5
mg of mannoside 6/kg at 30 min prior to urinary implantation.
Catheter implantation was immediately followed by transurethral
inoculation of UTI89. Based on pharmacokinetic studies, this
dose of mannoside 6 has been shown to be present in the bladder
above the 50% inhibitory concentrations for 8 h (8). Thus, IBC
formation was assayed by LacZ staining at 6 hpi. As shown in
Fig. 4A, mannoside treatment significantly reduced IBC forma-
tion (P  0.0051) in implanted animals. These findings indicate
that mannoside 6 prevents bacterial invasion into the bladder tis-
sue. If translated to a human application, prevention of bacterial
invasion into bladder tissue could enhance the efficacy of current
management protocols of removing the catheter (56) by prevent-
ing bladder colonization and thus preventing CAUTI.
Mannoside treatment increases the efficiency of TMP-SMZ
in preventing UPEC colonization.Mannosides have been shown
to potentiate the efficacy of TMP-SMZ when used in a combina-
tion treatment (8). This is due to the mechanism of action of
mannosides in that they prevent bacterial invasion into bladder
tissue and thus sequester bacteria to an extracellular niche. Since
TMP-SMZ concentrates in the urine, this mechanism of action of
mannosides results in bacterial exposure to increased concentra-
tions of TMP-SMZ (8). Thus, the ability of mannosides to poten-
tiate TMP-SMZ for the prevention of CAUTI was investigated by
treating animals with 54 and 270 g of TMP-SMZ/ml, respec-
tively, in their drinking water for 3 days followed by treatment
with saline or mannoside 6 (5 mg/kg) i.p. 30 min prior to implan-
tation and bacterial inoculation. Treatment with mannoside or
saline alone was also investigated. As shown in Fig. 4B,mannoside
only treatment significantly reduced bladder colonization (P 
0.0114) in implanted animals but did not significantly prevent
biofilm buildup on the catheter implant in vivo compared to sa-
line-treated animals (P  0.0547) (Fig. 4B). In previous studies,
mannoside 6 was significantly more effective in preventing blad-
der colonization than TMP-SMZ at 6 hpi (8) however this was not
the case in the presence of the catheter implant (Fig. 4B). How-
ever, in combination, mannoside potentiated the efficacy of
TMP-SMZ resulting in a significant decrease in UPEC coloniza-
tion of implants and bladders compared to treatment with antibi-
otic alone (P	 0.0005 in all cases) (Fig. 4B), as has been previously
observed in the absence of catheters (8). These data establish the
efficacy of combinatorial therapy for prevention of UPEC CAUTI
in this model and suggest that further optimization of pharmaco-
kinetic properties of the mannosides may improve the efficacy of
mannosides in the presence of a catheter implant.
DISCUSSION
UPEC is the major etiological agent of CAUTI (22). However, the
molecular mechanisms of urinary catheter and bladder coloniza-
tion after urinary catheterization have not been elucidated. Stud-
FIG 3 Deletion of fimH reduces biofilm formation and attenuates UPEC vir-
ulence. Graphs represent crystal violet-based quantification (A) andCFU enu-
meration in a logarithmic scale (log scale) (B) of 24-h-old UTI89 and
UTI89fimH (fimH) biofilms under human urine flow on silicone tubing at
37°C, indicating that the fimH strain is defective in biofilm formation under
these conditions. The bars representmeans of three independent experiments,
and error bars indicate the standard errors of the mean. The P values were
determined using theMann-Whitney U test. (C) Graph representing bacterial
titers in log scale recovered from implants and homogenized bladders of non-
implanted (open symbols) and implanted (closed symbols) infected with ei-
ther UTI89 (squares) or UTI89fimH (circles) for 24 h. Horizontal dashed
lines represent the limit of detection for viable bacteria. Each symbol repre-
sents a mouse from at least two independent experiments with n  5/group.
The horizontal bars represent themedian of each data set. *, P	 0.05; ***, P	
0.0005 (as determined by the Mann-Whitney U test).
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ies in an optimizedmurine model of foreign body-associated UTI
(18) show that urinary catheterization favors UPEC exploitation
of the bladder extracellular milieu. We showed here that this oc-
curs via type 1 pilus-dependent biofilm formation on the surface
of silicone implants in the murine bladder. Thus, type 1 pili me-
diate implant and bladder colonization during CAUTI, providing
definitive experimental evidence for previous reports postulating
that type 1 pili may be required for UPEC persistence during
CAUTIs (34). Interestingly, fimH-deficient UPEC strains have the
ability to adhere and colonize the foreign body, albeit at signifi-
cantly lower levels. This suggests the involvement of multiple bio-
film determinants in this process (24) although mutant strains
unable to express curli, S pili or flagella behaved similar to wild-
type UTI89 in the murine model of CAUTI.
The absence of bacteriuria may not reflect the bacteriologic
state of the bladder (51). QIRs can be established during an acute
UTI and persist in the bladder tissue even upon resolution of
bacteriuria. QIRs have been shown to be able to reemerge to cause
recurrent UTI following damage to the uroepithelium (37, 52).
Our findings indicate that urinary implantation of animals having
resolved bacteriuria from a previous UTI, can present with recur-
rent bacteriuria with the original strain, strongly suggesting that
tissue-associated reservoirs, which persist in the absence of bacte-
riuria, can provide a nidus for catheter colonization and lead to
CAUTI. Thus, although CAUTImay be caused by introduction of
bacteria into the urinary tract from the GI and vaginal tracts and
periurethral areas (16), our murine model indicates that bacterial
reservoirs existing within the urinary tract in the absence of bac-
teriuria may also serve as a nidus for CAUTI. These findings un-
derscore the need for future epidemiological studies on the con-
tribution of UPEC reservoirs in the establishment of rUTIs and
CAUTIs.
In the presence of the silicone implant in the bladder lumen,
IBC formation, a type 1 pilus-mediated process during UPEC
pathogenesis, is significantly reduced compared to nonimplanted
animals. After urinary catheterization, increased exfoliation or
damage to the uroepithelium results in a denuded epithelium (9,
12, 17, 18, 28, 33, 44), a condition that does not efficiently support
IBC formation, which is thought to occur only in terminally dif-
ferentiated superficial umbrella cells. Thus, by day 5 after implan-
tation of abacteriuric animals with a history of UTI, there is a
significant reduction in bacterial bladder CFU compared to non-
implanted animals. A similar effect has been observed previously
wherein denuding the uroepitheliumofUPEC-infectedmice at 14
dpi with protamine sulfate resulted in the clearance of QIRs and
tissue-associated bacteria in all of the treated animals (37). Thus,
urothelial exfoliation, either chemically or from urinary catheter-
ization, can lead to the elimination of tissue-associated reservoirs
that can otherwise serve as a nidus for rUTI. However, the tissue
damage and exfoliation caused by implantation is a double-edged
sword. Although it can result in immune-mediated clearance or
exfoliation of infected cells, an alternative outcome is that a pre-
existing reservoir may gain a foothold in the urinary tract by col-
onizing the catheter, which can subsequently lead to CAUTI.
FIG4 Mannoside treatment prevents IBC formation andUPEC virulencewhen used in combinationwith TMP-SMZ. (A)Graph representing IBC enumeration
fromLacZ staining of splayed bladders of female C57BL/6Ncrmice treated i.p. withmannoside or saline prior to transurethral implantation and inoculationwith
UTI89 at 6 hpi. Each symbol represents the IBC number from a single mouse from two independent experiments with n 5/group. The P value was determined
using theMann-WhitneyU test. (B)Graph representing bacterial titers in log scale recovered at 6 hpi from implants andhomogenized bladders of animals treated
with saline (Œ), mannoside (),TMP-SMZ (), and TMP-SMZ plus mannoside () prior to urinary implantation and inoculation with UTI89. Horizontal
dashed lines represent the limit of detection for viable bacteria. Each symbol represents a mouse from at least two independent experiments with n 5/group.
The horizontal bars represent the median of each data set. *, P 	 0.05; **, P 	 0.0005; ***, P 	 0.0005. ns, P  0.05. Significance was evaluated by using the
Mann-Whitney U test.
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The identification of FimH as a critical virulence factor during
UPEC CAUTI provides an avenue for the development of novel
preventative measures against these infections. There has recently
been an upsurge in recommendations and guidelines for manage-
ment of CAUTIs and rUTIs in catheterized patients, with a par-
ticular focus on preventative measures (53), including the limited
use of catheters, bacterial interference strategies, and even the pro-
phylactic use of antibiotics prior and following catheter removal
(7, 40, 56). However, the inappropriate use of antibiotics can ex-
acerbate the development of antibiotic resistance (3, 29, 40). We
have rationally designed small-molecule inhibitors of FimH called
mannosides (8, 19, 20) that block FimH-mediated functions. In a
murine model, we demonstrated that our mannosides were orally
bioavailable (19) and highly efficacious for the treatment and pre-
vention of chronic cystitis (8, 19). Thus, we investigated here their
utility in preventing CAUTIs. We discovered that pretreatment
with mannosides significantly prevented invasion and coloniza-
tion of the bladder epithelium following UPEC infection of im-
planted bladders. The inability of mannoside treatment to elimi-
nate UPEC from the implant, given that methyl mannose inhibits
UPEC biofilm on cathetermaterial in urine in vitro, may be due to
the lack of urine flow in this implanted murine model. Urine flow
through the catheter may enhance the efficacy of mannosides on
implant clearance. In addition, improved dosing schedules or use
of the newly optimized mannoside 8 or 10, which have better
potency and improved pharmacokinetic properties (8), may im-
prove the efficacy of mannoside in preventing biofilm formation
on the catheter in vivo.Mannosides have been shown to potentiate
the efficacy of TMP-SMZ and are able to convert clinically resis-
tant strains to becoming susceptible (8). This activity is due to the
mechanism of action of mannosides in preventing bacterial colo-
nization and invasion of bladder tissue thus sequestering bacteria
in the bladder lumen. TMP-SMZ is known to concentrate in the
urine to levels above theMIC (8).Here, we found thatmannosides
were also able to potentiate the efficacy of TMP-SMZ in prevent-
ing CAUTI. Future research will be focused on improving phar-
macokinetic properties and developing enhanced mannoside
compounds (19) that are effective at disrupting established bio-
films in vivo and exploring combination therapies with other
classes of biofilm inhibitors (4, 45).
Urinary catheterization is a necessary medical procedure that
causes major damage to the urinary tract. Pathogens, such as
UPEC, take advantage of this compromised environment to ex-
ploit new and existing niches and establish severe infections. This
report uncovers important molecular mechanisms underlying
UPEC pathogenesis following urinary catheterization and raises
important questions regarding the bacterial origins of urinary
catheter colonization and subsequent CAUTI. In humans, re-
moval of the contaminated urinary catheter is the preferred
method for treatment of theseCAUTI (57, 59).However, the pres-
ence of intracellular bacterial niches can serve as a nidus for recur-
rent UTI and CAUTI. If translated to application in humans, pro-
phylaxis with mannosides could reduce the rates of CAUTI by
preventing the ability of UPEC to colonize and invade the bladder
and possibly by also preventing biofilm formation on the catheter
material. In such instances, mannosides could potentially be used
in accordance with the current guidelines for management of
CAUTI and in combination with currently used antibiotics and
other potential preventative measures (53) prior to urinary cath-
eterization. This virulence-based combinatorial approach holds
promise to be able to reduce the rate of rUTIs and CAUTIs origi-
nating from gastrointestinal, vaginal and urinary tract bacterial
reservoirs, thus enhancing the efficacy of existing therapies.
ACKNOWLEDGMENTS
We thank Wandy Beatty for technical assistance with the CLSM, Osare-
noma Olomu and Richard Chole for providing technical assistance with
biofilm cultivation in the flow chamber system and peristaltic pumps
(Watson Marlow 205S), Drew Schwartz for technical assistance with the
IBC assays, and Kelly Wright for generating some of the mutants used in
this study.
This study was funded by National Institutes of Health grants
DK64540, DK51406, AI48689 (S.J.H.), and AI46433 (M.G.C.) and by an
ASM Robert D. Watkins Graduate Research Fellowship Award (P.S.G.).
REFERENCES
1. Alton G, Kjaergaard S, Etchison JR, Skovby F, Freeze HH. 1997. Oral
ingestion of mannose elevates blood mannose levels: a first step toward a
potential therapy for carbohydrate-deficient glycoprotein syndrome type
I. Biochem. Mol. Med. 60:127–133.
2. Anderson GG, et al. 2003. Intracellular bacterial biofilm-like pods in
urinary tract infections. Science 301:105–107.
3. Bi XC, et al. 2009. Pathogen incidence and antibiotic resistance patterns
of catheter-associated urinary tract infection in children. J. Chemother.
21:661–665.
4. Cegelski L, et al. 2009. Small-molecule inhibitors target Escherichia coli
amyloid biogenesis and biofilm formation. Nat. Chem. Biol. 5:913–919.
5. Chen SL, et al. 2009. Positive selection identifies an in vivo role for FimH
during urinary tract infection in addition tomannose binding. Proc. Natl.
Acad. Sci. U. S. A. 106:22439–22444.
6. Christensen BB, et al. 1999. Molecular tools for study of biofilm physi-
ology. Methods Enzymol. 310:20–42.
7. Conway LJ, Larson EL. 2012. Guidelines to prevent catheter-associated
urinary tract infection: 1980 to 2010. Heart Lung 41:271–283.
8. Cusumano CK, et al. 2011. Treatment and prevention of urinary tract
infection with orally active FimH inhibitors. Sci. Transl. Med. 3:109–115.
9. Delnay KM, Stonehill WH, Goldman H, Jukkola AF, Dmochowski RR.
1999. Bladder histological changes associated with chronic indwelling uri-
nary catheter. J. Urol. 161:1106–1109.
10. Dodson KW, et al. 2001. Structural basis of the interaction of the pyelo-
nephritic Escherichia coli adhesin to its human kidney receptor. Cell 105:
733–743.
11. Ejernaes K. 2011. Bacterial characteristics of importance for recurrent
urinary tract infections caused by Escherichia coli. Danish Med. Bull. 58:
B4187.
12. Elliott TS, Reid L, Rao GG, Rigby RC, Woodhouse K. 1989. Bladder
irrigation or irritation? Br. J. Urol. 64:391–394.
13. Eto DS, Jones TA, Sundsbak JL, Mulvey MA. 2007. Integrin-mediated
host cell invasion by type 1-piliated uropathogenic Escherichia coli. PLoS
Pathog. 3:e100. doi:10.1371/journal.ppat.0030100.
14. Ferrieres L, Hancock V, Klemm P. 2007. Specific selection for virulent
urinary tract infectious Escherichia coli strains during catheter-associated
biofilm formation. FEMS Immunol. Med. Microbiol. 51:212–219.
15. Firon N, Ashkenazi S, Mirelman D, Ofek I, Sharon N. 1987. Aromatic
alpha-glycosides of mannose are powerful inhibitors of the adherence of
type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells.
Infect. Immun. 55:472–476.
16. Garibaldi RA, Burke JP, Britt MR, Miller MA, Smith CB. 1980. Meatal
colonization and catheter-associated bacteriuria. N. Engl. J. Med. 303:
316–318.
17. Goble NM, Clarke T, Hammonds JC. 1989. Histological changes in the
urinary bladder secondary to urethral catheterisation. Br. J. Urol. 63:354–
357.
18. Guiton PS, Hung CS, Hancock LE, Caparon MG, Hultgren SJ. 2010.
Enterococcal biofilm formation and virulence in an optimized murine
model of foreign body-associated urinary tract infections. Infect. Immun.
78:4166–4175.
19. Han Z, et al. 2012. Lead optimization studies on FimH antagonists:
discovery of potent and orally bioavailable ortho-substituted biphenyl
mannosides. J. Med. Chem. 55:3945–3959.
Guiton et al.




arch 8, 2014 by W







20. Han Z, et al. 2010. Structure-based drug design and optimization of
mannoside bacterial FimH antagonists. J. Med. Chem. 53:4779–4792.
21. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren
SJ. 2010. Early severe inflammatory responses to uropathogenic Esche-
richia coli predispose to chronic and recurrent urinary tract infection.
PLoS Pathog. 6:e1001042. doi:10.1371/journal.ppat.1001042.
22. Hidron AI, et al. 2008. NHSN annual update: antimicrobial-resistant
pathogens associated with healthcare-associated infections: annual sum-
mary of data reported to the national health care safety network at the
Centers for Disease Control and Prevention, 2006–2007. Infect. Control
Hosp. Epidemiol. 29:996–1011.
23. Hung CS, et al. 2002. Structural basis of tropism of Escherichia coli to the
bladder during urinary tract infection. Mol. Microbiol. 44:903–915.
24. Jacobsen SM, Stickler DJ, Mobley HL, Shirtliff ME. 2008. Complicated
catheter-associated urinary tract infections due to Escherichia coli and Pro-
teus mirabilis. Clin. Microbiol. Rev. 21:26–59.
25. Justice SS, et al. 2004. Differentiation and developmental pathways of
uropathogenic Escherichia coli in urinary tract pathogenesis. Proc. Natl.
Acad. Sci. U. S. A. 101:1333–1338.
26. Justice SS, Lauer SR, Hultgren SJ, Hunstad DA. 2006. Maturation of
intracellular Escherichia coli communities requires SurA. Infect. Immun.
74:4793–4800.
27. Kucheria R, Dasgupta P, Sacks SH, Khan MS, Sheerin NS. 2005. Urinary
tract infections: new insights into a common problem. Postgrad. Med. J.
81:83–86.
28. Kurosaka Y, et al. 2001. A non-surgical rat model of foreign body-
associated urinary tract infection with Pseudomonas aeruginosa. Micro-
biol. Immunol. 45:9–15.
29. Magoha GA. 1997. Nosocomial infection of the urinary tract: pattern of
antibiotic use and drug resistance. East African Med. J. 74:190–192.
30. Martinez JJ, Hultgren SJ. 2002. Requirement of Rho-family GTPases in
the invasion of type 1-piliated uropathogenic Escherichia coli. Cell. Micro-
biol. 4:19–28.
31. Martinez JJ, Mulvey MA, Schilling JD, Pinkner JS, Hultgren SJ. 2000.
Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO
J. 19:2803–2812.
32. Martinez-MedinaM, et al. 2009. Biofilm formation as a novel phenotypic
feature of adherent-invasive Escherichia coli (AIEC). BMC Microbiol.
9:202. doi:10.1186/1471-2180-9-202.
33. McTaggart LA, Rigby RC, Elliott TS. 1990. The pathogenesis of urinary
tract infections associated with Escherichia coli, Staphylococcus saprophyti-
cus, and S. epidermidis. J. Med. Microbiol. 32:135–141.
34. Mobley HL, Chippendale GR, Tenney JH, Hull RA, Warren JW. 1987.
Expression of type 1 fimbriae may be required for persistence of Esche-
richia coli in the catheterized urinary tract. J. Clin. Microbiol. 25:2253–
2257.
35. Mulvey MA, et al. 1998. Induction and evasion of host defenses by type
1-piliated uropathogenic Escherichia coli. Science 282:1494–1497.
36. Mulvey MA, Schilling JD, Hultgren SJ. 2001. Establishment of a persis-
tent Escherichia coli reservoir during the acute phase of a bladder infection.
Infect. Immun. 69:4572–4579.
37. Mysorekar IU, Hultgren SJ. 2006. Mechanisms of uropathogenic Esche-
richia coli persistence and eradication from the urinary tract. Proc. Natl.
Acad. Sci. U. S. A. 103:14170–14175.
38. Mysorekar IU, Mulvey MA, Hultgren SJ, Gordon JI. 2002. Molecular
regulation of urothelial renewal and host defenses during infection with
uropathogenic Escherichia coli. J. Biol. Chem. 277:7412–7419.
39. Naves P, et al. 2008. Correlation between virulence factors and in vitro
biofilm formation by Escherichia coli strains. Microb. Pathog. 45:86–91.
40. Nazarko L. 2011. Should antibiotics be prescribed when urinary catheters
are removed? Br. J. Community Nursing 16:374–380.
41. Nicholson TF, Watts KM, Hunstad DA. 2009. OmpA of uropathogenic
Escherichia coli promotes postinvasion pathogenesis of cystitis. Infect. Im-
mun. 77:5245–5251.
42. Nielubowicz GR, Mobley HL. 2010. Host-pathogen interactions in uri-
nary tract infection. Nat. Rev. Urol. 7:430–441.
43. Parsons CL. 1986. Pathogenesis of urinary tract infections: bacterial ad-
herence, bladder defense mechanisms. Urol. C. N. Am. 13:563–568.
44. Peychl L, Zalud R. 2008. Changes in the urinary bladder caused by short-
term permanent catheter insertion. Casopis Lekaru Ceskych. 147:325–
329. (In Czech.)
45. Pinkner JS, et al. 2006. Rationally designed small compounds inhibit
pilus biogenesis in uropathogenic bacteria. Proc. Natl. Acad. Sci. U. S. A.
103:17897–17902.
46. Ronald LS, et al. 2008. Adaptive mutations in the signal peptide of the
type 1 fimbrial adhesin of uropathogenic Escherichia coli. Proc. Natl. Acad.
Sci. U. S. A. 105:10937–10942.
47. Rosen DA, Hooton TM, StammWE, Humphrey PA, Hultgren SJ. 2007.
Detection of intracellular bacterial communities in human urinary tract
infection. PLoS Med. 4:e329. doi:10.1371/journal.pmed.0040329.
48. Rosen DA, et al. 2008. Molecular variations in Klebsiella pneumoniae and
Escherichia coli FimHaffect function and pathogenesis in the urinary tract.
Infect. Immun. 76:3346–3356.
49. Saint S, Chenoweth CE. 2003. Biofilms and catheter-associated urinary
tract infections. Infect. Dis. Clin. N. Am. 17:411–432.
50. Sauer FG, et al. 1999. Structural basis of chaperone function and pilus
biogenesis. Science 285:1058–1061.
51. Schaeffer AJ, Schwan WR, Hultgren SJ, Duncan JL. 1987. Relationship
of type 1 pilus expression in Escherichia coli to ascending urinary tract
infections in mice. Infect. Immun. 55:373–380.
52. Schilling JD, Lorenz RG, Hultgren SJ. 2002. Effect of trimethoprim-
sulfamethoxazole on recurrent bacteriuria and bacterial persistence in
mice infected with uropathogenic Escherichia coli. Infect. Immun. 70:
7042–7049.
53. Siddiq DM, Darouiche RO. 2012. New strategies to prevent catheter-
associated urinary tract infections. Nat. Rev. Urol. 9:305–314.
54. Song J, et al. 2009. TLR4-mediated expulsion of bacteria from infected
bladder epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 106:14966–14971.
55. Sun TT, Zhao H, Provet J, Aebi U, Wu XR. 1996. Formation of
asymmetric unit membrane during urothelial differentiation. Mol. Biol.
Rep. 23:3–11.
56. Trautner BW. 2010. Management of catheter-associated urinary tract
infection. Curr. Opin. Infect. Dis. 23:76–82.
57. Trautner BW, Darouiche RO. 2004. Role of biofilm in catheter-
associated urinary tract infection. Am. J. Infect. Control 32:177–183.
58. Waksman G, Hultgren SJ. 2009. Structural biology of the chaperone-
usher pathway of pilus biogenesis. Nat. Rev. Microbiol. 7:765–774.
59. Warren JW. 2001. Catheter-associated urinary tract infections. Int. J.
Antimicrob. Agents 17:299–303.
60. Weissman SJ, et al. 2007. Differential stability and trade-off effects of
pathoadaptive mutations in the Escherichia coli FimH adhesin. Infect. Im-
mun. 75:3548–3555.
61. Wellens A, et al. 2008. Intervening with urinary tract infections using
anti-adhesives based on the crystal structure of the FimH-oligomannose-3
complex. PLoS One 3:e2040. doi:10.1371/journal.pone.0002040.
62. Wright KJ, Seed PC, Hultgren SJ. 2007. Development of intracellular
bacterial communities of uropathogenicEscherichia coli depends on type 1
pili. Cell. Microbiol. 9:2230–2241.
63. Wright KJ, Seed PC, Hultgren SJ. 2005. Uropathogenic Escherichia coli
flagella aid in efficient urinary tract colonization. Infect. Immun. 73:7657–
7668.
64. Yu J, Lin JH, Wu XR, Sun TT. 1994. Uroplakins Ia and Ib, two major
differentiation products of bladder epithelium, belong to a family of four
transmembrane domain (4TM) proteins. J. Cell Biol. 125:171–182.
65. Zhou G, et al. 2001. Uroplakin Ia is the urothelial receptor for uropatho-
genic Escherichia coli: evidence from in vitro FimH binding. J. Cell Sci.
114:4095–4103.
Mannosides as Prophylactic Agents against UPEC CAUTI




arch 8, 2014 by W
ashington University in St. Louis
http://aac.asm
.org/
D
ow
nloaded from
 
